Lucira Health, an Emeryville, CA-based developer of instrument-free, molecular infectious disease testing products, closed $15m Series B equity financing.
The round was led by Seraph Group, with participation from Eclipse Ventures, DCVC (Data Collective), Y Combinator and Sunstone Management and new backer ShangBay Capital.
The company intends to use the funds to finance regulatory clearances and early commercialization.
Founded in 2013 and led by Erik Engelson, CEO, Lucira Health is developing DNA- and RNA-based diagnostic tools for infectious diseases such as respiratory illnesses, sexually transmitted infections and others. The first application is influenza detection. The battery-powered device quickly analyzes a nasal swab sample and displays the result as either influenza A, B or negative diagnosis.
Lucira Health’s test is fully disposable, and can be used just about anywhere.
Following the commercial launch of the professional-use product, the subsequent consumer-use product will pair with a smartphone app to directly connect the user to treatment options.